Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors

NCT00301756 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00301756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00301756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
December 31, 2012
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, primary peritoneal carcinoma, recurrent borderline ovarian surface epithelial-stromal tumor, recurrent ovarian carcinoma, stage iii borderline ovarian surface epithelial-stromal tumor, stage iii ovarian cancer, stage iv borderline ovarian surface epithelial-stromal tumor, stage iv ovarian cancer